In a filing, Acadia Pharmaceuticals Inc revealed its CEO DAVIS STEPHEN unloaded Company’s shares for reported $0.32 million on Mar 27 ’24. In the deal valued at $17.90 per share,17,714 shares were sold. As a result of this transaction, DAVIS STEPHEN now holds 118,842 shares worth roughly $2.14 million.
Then, Schneyer Mark C. sold 5,434 shares, generating $97,269 in total proceeds. Upon selling the shares at $17.90, the EVP, CHIEF FINANCIAL OFFICER now owns 26,183 shares.
Before that, Teehan Brendan sold 5,140 shares. Acadia Pharmaceuticals Inc shares valued at $92,006 were divested by the EVP, COO, HEAD OF COMMERCIAL at a price of $17.90 per share. As a result of the transaction, Teehan Brendan now holds 36,340 shares, worth roughly $0.65 million.
Needham reiterated its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy in a research note published on March 12, 2024; the price target was $32. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid March from “a Buy” to “a Neutral”. Robert W. Baird began covering ACAD with “an Outperform” recommendation on January 30, 2024. Needham revised its rating on January 24, 2024. It rated ACAD as “a Buy” which previously was an “a Hold”.
Price Performance Review of ACAD
On Friday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -0.22% to $18.01. Over the last five days, the stock has lost -2.60%. Acadia Pharmaceuticals Inc shares have fallen nearly -42.48% since the year began. Nevertheless, the stocks have fallen -2.54% over the past one year. While a 52-week high of $33.99 was reached on 01/02/24, a 52-week low of $17.56 was recorded on 03/25/24. SMA at 50 days reached $22.78, while 200 days put it at $25.05. A total of 1.52 million shares were traded, compared to the trading of 1.33 million shares in the previous session.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 17.66, which if violated will result in even more drops to 17.32. On the upside, there is a resistance level at 18.30. A further resistance level may holdings at 18.60. The Relative Strength Index (RSI) on the 14-day chart is 30.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.64%. Stochastics %K at 36.61% indicates the stock is a holding.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 1.21 million shares to a total of 10.63 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 9.42 million shares. There was a rise of 11.38%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 8.62% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.43.
